NASDAQ:CRBP

Corbus Pharmaceuticals Stock Forecast, Price & News

$2.11

-0.25 (-10.59 %)

(As of 01/22/2021 04:45 PM ET)

Add

Compare

Today's Range

$2.07

Now: $2.11▼

$2.23

50-Day Range

$1.25

MA: $1.43▼

$1.74

52-Week Range

$0.91

Now: $2.11▼

$9.78

Volume12.92 million shs

Average Volume10.72 million shs

Market Capitalization$177.32 million

P/E RatioN/A

Dividend YieldN/A

Beta2.14

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.70 out of 5 stars

Medical Sector

205th out of 1,922 stocks

Pharmaceutical Preparations Industry

103rd out of 769 stocks

3.2 Analyst's Opinion

Consensus Rating
Corbus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.39, Corbus Pharmaceuticals has a forecasted upside of 1,150.7% from its current price of $2.11.
Amount of Analyst Coverage
Corbus Pharmaceuticals has received no research coverage in the past 90 days.

3.0 Community Rank

Outperform Votes
Corbus Pharmaceuticals has received 416 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Corbus Pharmaceuticals has received 276 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Corbus Pharmaceuticals has received 60.12% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote “Outperform” if you believe CRBP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Corbus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corbus Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corbus Pharmaceuticals insiders have sold 2,598.73% more of their company's stock than they have bought. Specifically, they have bought $10,261.00 in company stock and sold $276,917.00 in company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Corbus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
67.13% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($1.59) to ($0.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corbus Pharmaceuticals is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corbus Pharmaceuticals is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Corbus Pharmaceuticals has a P/B Ratio of 21.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CRBP

Previous Symbol

CUSIPN/A

CIK1595097

Webwww.corbuspharma.com

Phone617-963-0100

Employees141

Debt

Debt-to-Equity Ratio0.61

Current Ratio2.06

Quick Ratio2.06

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$36.14 million

Price / Sales4.91

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.10 per share

Price / Book21.10

Profitability

EPS (Most Recent Fiscal Year)($1.12)

Net Income$-71,450,000.00

Net Margins-2,208.06%

Return on Equity-485.45%

Return on Assets-167.68%

Miscellaneous

Outstanding Shares84,037,000

Market Cap$177.32 million

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

$2.11

-0.25 (-10.59 %)

(As of 01/22/2021 04:45 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

How has Corbus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRBP stock has decreased by 48.3% and is now trading at $2.13.
View which stocks have been most impacted by COVID-19.

Is Corbus Pharmaceuticals a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Corbus Pharmaceuticals?

Wall Street analysts have given Corbus Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Corbus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Corbus Pharmaceuticals' CEO?

1,448 employees have rated Corbus Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Corbus Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Corbus Pharmaceuticals.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its quarterly earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.42). The biopharmaceutical company had revenue of $1.23 million for the quarter, compared to the consensus estimate of $3.42 million. Corbus Pharmaceuticals had a negative net margin of 2,208.06% and a negative return on equity of 485.45%.
View Corbus Pharmaceuticals' earnings history.

What price target have analysts set for CRBP?

9 Wall Street analysts have issued 1-year target prices for Corbus Pharmaceuticals' stock. Their forecasts range from $2.50 to $112.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $26.39 in the next year. This suggests a possible upside of 1,138.9% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Corbus Pharmaceuticals' key competitors?

Some companies that are related to Corbus Pharmaceuticals include MannKind (MNKD), Merus (MRUS), Aclaris Therapeutics (ACRS), Avid Bioservices (CDMO), ZIOPHARM Oncology (ZIOP), Gossamer Bio (GOSS), Calliditas Therapeutics AB (publ) (CALT), Odonate Therapeutics (ODT), VBI Vaccines (VBIV), Inventiva (IVA), Esperion Therapeutics (ESPR), Foghorn Therapeutics (FHTX), Syros Pharmaceuticals (SYRS), AnaptysBio (ANAB) and Zafgen (ZFGN).
View all of CRBP's competitors.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:

Dr. Yuval Cohen, CEO & Director (Age 45, Pay $810.55k)
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 62, Pay $520k)
Dr. Barbara White, Head of Research & Chief Medical Officer (Age 70, Pay $570.7k)
Ted Jenkins, Sr. Director of Investor Relations & Corp. Communications
Dr. Mark A. Tepper, Co-Founder & Consultant (Age 63)
Scott Constantine, Sr. Director & Head of Clinical Operations
Mr. Craig Stuart Millian M.B.A., Chief Commercial Officer (Age 52)
Sergei Atamas, Exec. Director of Research

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Kestra Advisory Services LLC (0.03%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends for Corbus Pharmaceuticals.

Which major investors are selling Corbus Pharmaceuticals stock?

CRBP stock was sold by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC.
View insider buying and selling activity for Corbus Pharmaceuticals or view top insider-selling stocks.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $2.13.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $179.00 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 141 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here